



(11) **EP 3 349 581 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**05.01.2022 Bulletin 2022/01**

(45) Date of publication and mention  
of the grant of the patent:  
**01.12.2021 Bulletin 2021/48**

(21) Application number: **16847305.6**

(22) Date of filing: **15.09.2016**

(51) Int Cl.:  
**C07D 401/12** <sup>(2006.01)</sup> **C07D 413/12** <sup>(2006.01)</sup>  
**C07D 417/12** <sup>(2006.01)</sup> **C07D 417/14** <sup>(2006.01)</sup>  
**C07D 243/38** <sup>(2006.01)</sup> **C07D 453/02** <sup>(2006.01)</sup>  
**C07D 471/04** <sup>(2006.01)</sup> **C07D 267/20** <sup>(2006.01)</sup>  
**C07D 281/16** <sup>(2006.01)</sup> **A61K 31/551** <sup>(2006.01)</sup>  
**A61K 31/553** <sup>(2006.01)</sup> **A61K 31/554** <sup>(2006.01)</sup>  
**A61P 31/20** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2016/051949**

(87) International publication number:  
**WO 2017/048962 (23.03.2017 Gazette 2017/12)**

(54) **HEPATITIS B CORE PROTEIN MODULATORS**

HEPATITIS-B-KERN-PROTEINMODULATOREN

MODULATEURS DES PROTÉINES DU NOYAU DE L'HÉPATITE B

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **15.09.2015 US 201562218815 P**

(43) Date of publication of application:  
**25.07.2018 Bulletin 2018/30**

(73) Proprietors:  
• **Assembly Biosciences, Inc.**  
**South San Francisco, CA 94080 (US)**  
• **Indiana University Research and Technology**  
**Corporation**  
**Bloomington IN 47405 (US)**

(72) Inventors:  
• **TURNER, William**  
**Bloomington, IN 47408 (US)**

• **MAAG, Hans**  
**79692 Kleires Wiesental (DE)**  
• **FRANCIS, Samson**  
**Indianapolis, IN 46204 (US)**

(74) Representative: **Harris, Jennifer Lucy et al**  
**Kilburn & Strode LLP**  
**Lacon London**  
**84 Theobalds Road**  
**London WC1X 8NL (GB)**

(56) References cited:  
**WO-A1-2013/006394 WO-A1-2015/017412**  
**WO-A1-2015/138895 US-A1- 2007 105 835**

• **DATABASE PUBCHEM [Online] 09 August 2005**  
**XP055371494 Database accession no. 201327**  
• **XIAO ET AL.: 'Discovery, Optimization, and**  
**Characterization of Novel D2 Dopamine Receptor**  
**Selective Antagonists' J MED CHEM. vol. 57,**  
**2014, pages 3450 - 3463, XP055140768**

**EP 3 349 581 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).